33 results on '"Lianghao Zhang"'
Search Results
2. Correction: Long non-coding RNA SOX2OT promotes the stemness phenotype of bladder cancer cells by modulating SOX2
- Author
-
Yonghao Zhan, Zhicong Chen, Shiming He, Yanqing Gong, Anbang He, Yifan Li, Lianghao Zhang, Xuepei Zhang, Dong Fang, Xuesong Li, and Liqun Zhou
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Published
- 2023
- Full Text
- View/download PDF
3. The enhancer RNA ADCY10P1 is associated with the progression of ovarian cancer
- Author
-
Jiaya Mo, Lianghao Zhang, Huiqing Li, Haoran Duan, Dong Wang, Xiaolei Zhao, and Ya Xie
- Subjects
Ovarian cancer ,Enhancer RNAs ,Prognosis ,Proliferation ,Metastasis ,Gynecology and obstetrics ,RG1-991 - Abstract
Abstract Background Emerging evidence identifies enhancer RNAs (eRNAs) as a class of regulatory ncRNAs that can contribute to the transcription of target genes. In this study, we used an integrated data analysis method to identify the important role of eRNAs in ovarian cancer (OC). Methods Gene expression profiles and clinical information from The Cancer Genome Atlas (TCGA) database were used for this study. Based on expression analysis using GEPIA2 gene and Kaplan–Meier survival was performed to ensure the significance of the selected enhancer RNA ADCY10P1 in OC. Next, we explored the correlation and clinical significance between ADCY10P1 and target gene NFYA. Furthermore, we evaluated the effects of overexpression of ADCY10P1 on the proliferation, migration, invasion and epithelial-mesenchymal transformation (EMT) of OC cell lines. We also investigated the biological function enrichment score of ADCY10P1 and verified it with OC cell lines. Finally, external validation was conducted, and the prognostic value of the ADCY10P1 in different tumors was demonstrated. Results We selected the eRNA ADCY10P1 associated with OC prognosis, with NFYA as its predicted target gene. Low ADCY10P1 expression was found to be associated with poor overall survival, high histological grade, and advanced stage of OC. Additionally, overexpression of ADCY10P1 inhibited the proliferation, migration, invasion and EMT phenotype of OC cell lines. Furthermore, ADCY10P1 was observed to inhibit glycolysis and fatty acid metabolism, thereby affecting OC progression. Meanwhile, OC tissue samples were externally validated. In addition, the pan-cancer analysis revealed that ADCY10P1 had prognostic value in other cancers. Conclusions This study showed that ADCY10P1 plays a key role in OC progression and may facilitate prognosis prediction.
- Published
- 2022
- Full Text
- View/download PDF
4. CircOMA1 promotes tumour growth and metastasis of bladder cancer by modulating IGF‐IR/MAPK/EMT pathway
- Author
-
Lianghao Zhang, Yonghao Zhan, Longqing Li, Haotian Deng, Jiange Wang, Zhaowei Zhu, and Xuepei Zhang
- Subjects
Medicine (General) ,R5-920 - Published
- 2022
- Full Text
- View/download PDF
5. Long non-coding RNA CASC9 promotes tumor growth and metastasis via modulating FZD6/Wnt/β-catenin signaling pathway in bladder cancer
- Author
-
Yonghao Zhan, Lianghao Zhang, Shuanbao Yu, Jianguo Wen, Yuchen Liu, and Xuepei Zhang
- Subjects
Bladder cancer ,CASC9 ,FZD6 ,lncRNA ,miR-497-5p ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Accumulating evidence have highlighted the importance of long noncoding RNAs (lncRNAs) in multiple cancers development and progression. Cancer susceptibility candidate 9 (CASC9) is a novel long non-coding RNA and plays important regulatory role in diverse biological processes of cancers. However, the clinical significance and molecular mechanism of CASC9 in bladder cancer is still unknown. Methods Comprehensive lncRNAs profiling analysis were conducted to identify lncRNAs profile alterations and uncover valuable lncRNA candidates for bladder cancer. The expression level of CASC9 was determined in a total of 106 patients with bladder cancer. Loss-of-function experiments were performed to identify the functions of CASC9 in tumor growth and metastasis of bladder cancer in vitro and in vivo. Bioinformatics analysis and further experiments were performed to explore the molecular mechanisms underlying the functions of CASC9. Results This study found that CASC9 expression was markedly upregulated in bladder cancer and related to histological grade, TNM stage and prognosis. Knockdown of CASC9 inhibited tumor growth and metastasis of bladder cancer in vitro and in vivo. Mechanistically, we found that CASC9 functions as a miRNA sponge to positively regulate FZD6 expression and subsequently activates Wnt/β-catenin signaling pathway, thus playing an oncogenic role in bladder cancer pathogenesis. Conclusion In summary, lncRNA CASC9 plays a critical regulatory role in bladder cancer. The CASC9/miR-497-5p/ FZD6 axis provides insights for regulatory mechanism of bladder cancer, and new strategies for clinical practice.
- Published
- 2020
- Full Text
- View/download PDF
6. Long non-coding RNA SOX2OT promotes the stemness phenotype of bladder cancer cells by modulating SOX2
- Author
-
Yonghao Zhan, Zhicong Chen, Shiming He, Yanqing Gong, Anbang He, Yifan Li, Lianghao Zhang, Xuepei Zhang, Dong Fang, Xuesong Li, and Liqun Zhou
- Subjects
SOX2OT ,Cancer stem cell ,miR-200c ,SOX2 ,Bladder cancer ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Accumulating evidence indicates that long non-coding RNAs (lncRNAs) are potential biomarkers and key regulators of tumour development and progression. SOX2 overlapping transcript (SOX2OT) is a novel lncRNA that acts as a potential biomarker and is involved in the development of cancer and cancer stem cells. However, the clinical significance and molecular mechanism of SOX2OT in bladder cancer are still unknown. Methods The expression level of SOX2OT was determined by RT-qPCR in a total of 106 patients with urothelial bladder cancer and in different bladder cancer cell (BCC) lines. Bladder cancer stem cells (BCSCs) were isolated from BCCs using flow cytometry based on the stem cell markers CD44 and ALDH1. Loss-of-function experiments were performed to investigate the biological roles of SOX2OT in the stemness phenotype of BCSCs. Comprehensive transcriptional analysis, RNA FISH, dual-luciferase reporter assays and western blots were performed to explore the molecular mechanisms underlying the functions of SOX2OT. Results SOX2OT was highly expressed in bladder cancer, and increased SOX2OT expression was positively correlated with a high histological grade, advanced TNM stage and poor prognosis. Further experiments demonstrated that knockdown of SOX2OT inhibited the stemness phenotype of BCSCs. Moreover, inhibition of SOX2OT delayed xenograft tumour growth and decreased metastases in vivo. Mechanistically, we found that SOX2OT was mainly distributed in the cytoplasm and positively regulated SOX2 expression by sponging miR-200c. Furthermore, SOX2 overexpression reversed the SOX2OT silencing-induced inhibition of the BCSC stemness phenotype. Conclusion This study is the first to demonstrate that SOX2OT plays an important regulatory role in BCSCs and that SOX2OT may serve as a potential diagnostic biomarker and therapeutic target in bladder cancer.
- Published
- 2020
- Full Text
- View/download PDF
7. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled, phase 1/2 trial
- Author
-
Wanshen Guo, Kai Duan, Yuntao Zhang, Zhiming Yuan, Yan-Bo Zhang, Zejun Wang, Dongyang Zhao, Huajun Zhang, Zhiqiang Xie, Xinguo Li, Cheng Peng, Wei Zhang, Yunkai Yang, Wei Chen, Xiaoxiao Gao, Wangyang You, Xue-Wei Wang, Zhengli Shi, Yanxia Wang, Xu-Qin Yang, Lianghao Zhang, Lili Huang, Qian Wang, Jia Lu, Yong-Li Yang, Jing Guo, Wei Zhou, Xin Wan, Cong Wu, Wenhui Wang, Jianhui Du, Xuanxuan Nian, Xing-Hang Li, Shihe Huang, Shuo Shen, Shengli Xia, An Pan, and Xiaoming Yang
- Subjects
Medicine (General) ,R5-920 - Abstract
Background: We aimed to assess the safety and immunogenicity of an inactivated vaccine against COVID-19 in Chinese adults aged ≥18 years. Methods: This is an ongoing randomized, double-blind, placebo-controlled, phase 1/2 clinical trial among healthy adults aged ≥18 years in Henan Province, China. Participants (n = 336 in 18–59 age group and n = 336 in ≥60 age group) were enrolled between April 12 and May 17 2020, and were equally randomized to receive vaccine or placebo (aluminum hydroxide adjuvant) in a three-dose schedule of 2·5, 5, or 10 µg on days 0, 28, and 56. Another 448 adults aged 18–59 years were equally allocated to four groups (a one-dose schedule of 10 µg, and two-dose schedules of 5 µg on days 0 and 14/21/28) and received vaccine or placebo (ratio 3:1 within each group). The primary outcomes were 7-day post-injection adverse reactions and neutralizing antibody titres on days 28 and 90 after the whole-course vaccination. Trial registration: www.chictr.org.cn #ChiCTR2000031809. Findings: The 7-day adverse reactions occurred in 4·8% to 32·1% of the participants in various groups, and most adverse reactions were mild, transient, and self-limiting. Twenty participants reported 68 serious adverse events which were judged to be unrelated to the vaccine. The 90-day post-injection geometric mean titres of neutralizing antibody ranged between 87 (95% CI: 61–125) and 129 (99–169) for three-dose schedule among younger and older adults; 20 (14–27), 53 (38–75), and 44 (32–61) in 5 µg days 0 and 14/21/28 groups, respectively, and 7 (6–9) in one-dose 10 µg group. There were no detectable antibody responses in all placebo groups. Interpretation: The inactivated vaccine against COVID-19 was well tolerated and immunogenic in both younger and older adults. The two-dose schedule of 5 µg on days 0 and 21/28 and three-dose schedules on days 0, 28, and 56 could be further evaluated for long-term safety and efficacy in the phase 3 trials. Funding: The study was funded by the National Program on Key Research Project of China (2020YFC0842100) and Major Science and Technology Project of the National New Drug Development of China (2018ZX09734-004).
- Published
- 2021
- Full Text
- View/download PDF
8. Identification of Immune-Related lncRNA Signature to Predict Prognosis and Immunotherapeutic Efficiency in Bladder Cancer
- Author
-
Lianghao Zhang, Longqing Li, Yonghao Zhan, Jiange Wang, Zhaowei Zhu, and Xuepei Zhang
- Subjects
bladder cancer ,The Cancer Genome Atlas ,immune-related long noncoding RNA ,prognosis ,tumor immune microenvironment ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
PurposeIdentify immune-related lncRNA (IRL) signature related to the prognosis and immunotherapeutic efficiency for bladder cancer (BLCA) patients.MethodsA total of 397 samples, which contained RNA-seq and clinical information from The Cancer Genome Atlas (TCGA) database, were used for the following study. Then the Lasso penalized Cox proportional hazards regression model was used to construct prognostic signature. According to the optimal cut-off value determined by time-dependent ROC curve, low and high-risk groups were set up. One immunotherapy microarray dataset as validation set was used to verify the ability of predicting immunotherapy efficacy. Furthermore, more evaluation between two risk groups related clinical factors were conducted. Finally, external validation of IRL-signature was conducted in Zhengzhou cohort.ResultFour IRLs (HCP5, IPO5P1, LINC00942, and LINC01356) with significant prognostic value (P
- Published
- 2021
- Full Text
- View/download PDF
9. Pelvic Lymph Node Dissection During Cystectomy for Patients With Bladder Carcinoma With Variant Histology: Does Histologic Type Matter?
- Author
-
Lijuan Guo, Lianghao Zhang, Jiange Wang, Xuepei Zhang, and Zhaowei Zhu
- Subjects
bladder neoplasms ,cystectomy ,histologic types ,pelvic lymph node dissection ,survival ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
PurposeAdding pelvic lymph node dissection (PLND) to cystectomy offers significant survival benefit. However, it remains unclear whether this benefit persists in all histologic types. The aim of the study was to examine the impact of PLND on overall survival (OS) after cystectomy in bladder carcinoma patients with histological variants.MethodsWithin the Surveillance, Epidemiology and End Results database, we identified 16,880 bladder carcinoma patients receiving cystectomy between 2004 and 2015. Patients were stratified according to the following histologic types: transitional cell carcinoma, squamous cell carcinoma, adenocarcinoma, small cell carcinoma, neuroendocrine carcinoma, signet ring cell carcinoma, pseudosarcomatous carcinoma, and other histology. Cox regression models were used to evaluate the effect of PLND on OS stratified by histologic type.ResultsHistologic types were significantly associated with the presence of lymph node metastasis in patients with bladder carcinoma (P < 0.001). In multivariable Cox regression analyses, PLND compared with non-PLND was associated with OS benefit in patients with transitional cell carcinoma (hazard ratio [HR], 0.595; 95% confidence interval [95% CI], 0.557–0.634 [P < 0.001]), squamous cell carcinoma (HR, 0.646; 95% CI, 0.494–0.846 [P = 0.002]), and signet ring cell carcinoma (HR, 0.233; 95% CI, 0.107–0.504 [P < 0.001]), whereas no significant differences in OS were observed in other histological subsets.DiscussionOur analyses revealed a significant OS benefit from PLND in patients with transitional cell carcinoma, squamous cell carcinoma, and signet ring cell carcinoma. However, a survival benefit of PLND in patients with other histologic types was not demonstrated.
- Published
- 2020
- Full Text
- View/download PDF
10. Deep SVBRDF Estimation from Single Image under Learned Planar Lighting.
- Author
-
Lianghao Zhang, Fangzhou Gao, Li Wang, Minjing Yu, Jiamin Cheng, and Jiawan Zhang
- Published
- 2023
- Full Text
- View/download PDF
11. Transparent Object Reconstruction via Implicit Differentiable Refraction Rendering.
- Author
-
Fangzhou Gao, Lianghao Zhang, Li Wang, Jiamin Cheng, and Jiawan Zhang
- Published
- 2023
- Full Text
- View/download PDF
12. DeepBasis: Hand-Held Single-Image SVBRDF Capture via Two-Level Basis Material Model.
- Author
-
Li Wang, Lianghao Zhang, Fangzhou Gao, and Jiawan Zhang
- Published
- 2023
- Full Text
- View/download PDF
13. Deep Uncalibrated Photometric Stereo via Inter-Intra Image Feature Fusion.
- Author
-
Fangzhou Gao, Meng Wang, Lianghao Zhang, Li Wang, and Jiawan Zhang
- Published
- 2022
- Full Text
- View/download PDF
14. Application Effectiveness of Segment IV Portal Vein Reconstruction for Early Postoperative Liver Function Recovery in Split Liver Transplantation
- Author
-
Muhammad, Imran, primary, Rehman, Faisal U. L., additional, Wang, Feng, additional, Xiong, Xiaopeng, additional, Lianghao, Zhang, additional, and Jinzhen, Cai, additional
- Published
- 2023
- Full Text
- View/download PDF
15. A cost-effective diagnostic approach of urothelial carcinomas in 2 mL full voided urine based on novel panels of dual methylated DNA markers
- Author
-
Jian Fan, Chang Meng, Yucai Wu, Di Cai, Shiming He, Zhihua Li, Lianghao Zhang, Kunlin Yang, Aixiang Wang, Xinfei Li, Yicong Du, Shengwei Xiong, Tingting Li, Lanlan Dong, Yanqing Gong, Liqun Zhou, and Xuesong Li
- Abstract
Background: Currently, universal methylated biomarkers for urothelial carcinomas are lacking, and nearly all the diagnostic panels for bladder cancer with accuracy over 90% are multiplex (> 3 markers), and based on large volume urine (> 50 mL), which are not cost-effective for clinical application. The aim of this study was to identify universal marker for urothelial carcinomas based on 2 mL full voided urine. Method: In this study, we discovered the top 25 differential methylation regions with a sliding window method using TCGA cohort, and 8 were validated in 30 healthy blood and 20 normal urine samples by Sanger sequencing, three new regions chr10:101140373-101140735 (hg38), GRASP and AL021918.2 with specificities ≥90% were further validated in 103 tissues (47 bladder cancer and 28 paired carcinoma and normal adjacent tissues of renal pelvis (n=14) and ureter (n=14)), then chr10:101140373-101140735 and AL021918.2 were tested in 2mL urine from 477 participants (199 bladder cancer, 39 renal pelvis and 26 ureter carcinomas, and 213 negative samples including other urological carcinomas and benign diseases), two widely reported bladder cancer biomarkers, TWIST1 and VIM, were also detected in tissue and urine samples for comparison, the technology platform was methylation-specific PCR. Results: The AUC values of AL021918.2 was highest both in tissue and urine samples in classfying urothelial carcinomas and adjacent normal/negative samples. Overally, In urine, the sensitivities and specificities of AL021918.2 for urothelial carcinomas were 87.12% and 93.90%, specifically, the sensitivities for low-grade bladder cancer, Ta stage bladder cancer, low-grade upper urinary tract urothelial carcinomas were 75.56%, 83.33% and 100%, respectively. When AL021918.2and VIM were combined, the sensitivity for urothelial carcinomas could reach 93.94%, and the specificity was 92.02%, the sensitivities of the dual-targets panel for Ta stage and low-grade urothelial carcinomas were both higher than 90%. Conclusions: We found a novel and general urothelial carcinoma biomarker AL021918.2, outperfoming the existing two bladder cancer markers. The combination of AL021918.2 and VIMhad accuracy over 90%, in addition, only 2mL full voided urine was used, greatly improving the simplicity, which had important clinical implications in future applications.
- Published
- 2023
16. Low power dissipation SiGe HBT dual-band variable gain amplifier.
- Author
-
Hongyun Xie, Shuo Liu, Lianghao Zhang, Zhiyun Jiang, Yanxiao Zhao, Liang Chen, and Wanrong Zhang 0002
- Published
- 2015
- Full Text
- View/download PDF
17. Long non-coding RNA CASC9 promotes tumor growth and metastasis via modulating FZD6/Wnt/β-catenin signaling pathway in bladder cancer
- Author
-
Yuchen Liu, Xuepei Zhang, Lianghao Zhang, Shuanbao Yu, Yonghao Zhan, and Jianguo Wen
- Subjects
0301 basic medicine ,Male ,Cancer Research ,Lung Neoplasms ,Apoptosis ,Metastasis ,Mice ,0302 clinical medicine ,lncRNA ,Cell Movement ,Tumor Cells, Cultured ,beta Catenin ,CASC9 ,Gene knockdown ,Mice, Inbred BALB C ,Bladder cancer ,Wnt signaling pathway ,Middle Aged ,Prognosis ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Long non-coding RNA ,Gene Expression Regulation, Neoplastic ,Survival Rate ,Oncology ,030220 oncology & carcinogenesis ,Female ,RNA, Long Noncoding ,Signal transduction ,FZD6 ,Mice, Nude ,Wnt1 Protein ,Biology ,lcsh:RC254-282 ,03 medical and health sciences ,Downregulation and upregulation ,miR-497-5p ,medicine ,Biomarkers, Tumor ,Animals ,Humans ,Cell Proliferation ,Research ,RNA ,medicine.disease ,Xenograft Model Antitumor Assays ,Frizzled Receptors ,MicroRNAs ,030104 developmental biology ,Urinary Bladder Neoplasms ,Cancer research - Abstract
Background Accumulating evidence have highlighted the importance of long noncoding RNAs (lncRNAs) in multiple cancers development and progression. Cancer susceptibility candidate 9 (CASC9) is a novel long non-coding RNA and plays important regulatory role in diverse biological processes of cancers. However, the clinical significance and molecular mechanism of CASC9 in bladder cancer is still unknown. Methods Comprehensive lncRNAs profiling analysis were conducted to identify lncRNAs profile alterations and uncover valuable lncRNA candidates for bladder cancer. The expression level of CASC9 was determined in a total of 106 patients with bladder cancer. Loss-of-function experiments were performed to identify the functions of CASC9 in tumor growth and metastasis of bladder cancer in vitro and in vivo. Bioinformatics analysis and further experiments were performed to explore the molecular mechanisms underlying the functions of CASC9. Results This study found that CASC9 expression was markedly upregulated in bladder cancer and related to histological grade, TNM stage and prognosis. Knockdown of CASC9 inhibited tumor growth and metastasis of bladder cancer in vitro and in vivo. Mechanistically, we found that CASC9 functions as a miRNA sponge to positively regulate FZD6 expression and subsequently activates Wnt/β-catenin signaling pathway, thus playing an oncogenic role in bladder cancer pathogenesis. Conclusion In summary, lncRNA CASC9 plays a critical regulatory role in bladder cancer. The CASC9/miR-497-5p/ FZD6 axis provides insights for regulatory mechanism of bladder cancer, and new strategies for clinical practice.
- Published
- 2020
18. Effectiveness of convalescent plasma therapy in severe COVID-19 patients
- Author
-
Bei Li, Cheng Peng, Xinxin Zhang, Min Zhou, Zejun Wang, Huichuan Yang, Yue Wang, Li Li, Shengli Meng, Li Chen, Shihe Huang, Li Cesheng, Jiayou Zhang, Kun Deng, Hu Yong, Yanping Xu, Wei Zhang, Xiaoxiao Gao, Peng Yan, Wei Chen, Kai Duan, Zhou Zhijun, Ding Yu, Xiaoming Yang, Lianghao Zhang, Gong Qin, Jianhong Yu, Zhengli Shi, Huajun Zhang, Xiaobei Zheng, Dan Wang, Jinyan Huang, Xiao Wu, Jieming Qu, Xuefei Liu, Yeqin Hu, Mingchao Yuan, Dongbo Zhou, Zhu Chen, Zhiwu Xia, Jifeng Hou, Xiaoqi Yu, Lin Lianzhen, Ting Yu, Zhang Zhi, Bende Liu, Sai-Juan Chen, and Ying Liu
- Subjects
medicine.medical_specialty ,Multidisciplinary ,biology ,business.industry ,Lymphocyte ,Viremia ,medicine.disease ,Gastroenterology ,Respiratory pharmacology ,medicine.anatomical_structure ,Internal medicine ,medicine ,biology.protein ,Clinical endpoint ,Antibody ,Neutralizing antibody ,Adverse effect ,business ,Viral load - Abstract
Currently, there are no approved specific antiviral agents for novel coronavirus disease 2019 (COVID-19). In this study, 10 severe patients confirmed by real-time viral RNA test were enrolled prospectively. One dose of 200 mL of convalescent plasma (CP) derived from recently recovered donors with the neutralizing antibody titers above 1:640 was transfused to the patients as an addition to maximal supportive care and antiviral agents. The primary endpoint was the safety of CP transfusion. The second endpoints were the improvement of clinical symptoms and laboratory parameters within 3 d after CP transfusion. The median time from onset of illness to CP transfusion was 16.5 d. After CP transfusion, the level of neutralizing antibody increased rapidly up to 1:640 in five cases, while that of the other four cases maintained at a high level (1:640). The clinical symptoms were significantly improved along with increase of oxyhemoglobin saturation within 3 d. Several parameters tended to improve as compared to pretransfusion, including increased lymphocyte counts (0.65 × 10 9 /L vs. 0.76 × 10 9 /L) and decreased C-reactive protein (55.98 mg/L vs. 18.13 mg/L). Radiological examinations showed varying degrees of absorption of lung lesions within 7 d. The viral load was undetectable after transfusion in seven patients who had previous viremia. No severe adverse effects were observed. This study showed CP therapy was well tolerated and could potentially improve the clinical outcomes through neutralizing viremia in severe COVID-19 cases. The optimal dose and time point, as well as the clinical benefit of CP therapy, needs further investigation in larger well-controlled trials.
- Published
- 2020
19. Effectiveness of the inactivated enterovirus 71 vaccine in children aged 6–35 months: protocol for a multicentre, case-control phase IV clinical trial
- Author
-
Xuefeng Zhang, Pengfei Jin, Wenqi Shen, Lianghao Zhang, Kai Duan, Fengcai Zhu, and Jinxing Li
- Subjects
Protocol (science) ,Pediatrics ,medicine.medical_specialty ,biology ,business.industry ,Public Health, Environmental and Occupational Health ,Context (language use) ,Odds ratio ,biology.organism_classification ,Logistic regression ,Vaccination ,Clinical trial ,Immunization ,Emergency Medicine ,Enterovirus 71 ,Medicine ,business - Abstract
Background: Inactivated enterovirus 71 (EV-A71) vaccines have already be introduced for routine childhood immunization in mainland China since 2016. However, it is not well known that the effectiveness of EV-A71 vaccine under ‘real world’ conditions. We aimed to assess the effectiveness and safety of EV-A71 vaccine against EV-A71 associated hand foot and mouth disease (HFMD) in children aged 6–35 months. Methods: This is a multicentre, phase IV, case-control study of the inactivated EV-A71 vaccine. Through the hospital-based active surveillance of HFMD, a case-control study design with two groups of controls (test-negative control and community control) will be used to estimate vaccine effectiveness of EV-A71 vaccine. We will recruit cases defined as patients aged 6–47 months admitted to presenting hospitals for laboratory-confirmed HFMD induced by EV-A71. For each case, hospital test-negative control and community control are selected. Vaccination status will be determined from electronic immunization records (EIRs) and parent-reported vaccination cards. Logistic regression analysis will be carried out to calculate vaccine effectiveness (one minus the odds ratio of vaccination) by comparing patients with HFMD cases who tested positive for EV-A71 with those who tested negative and with community controls. Discussion: This is the first evaluation of the performance of EV-A71 vaccines in the context of real-world immunization programs using case-control methodology with community controls and test-negative controls. The findings of this study will provide valid and reliable knowledge on the performance of EV-A71 vaccines in the real-world context. Trial registration: ClinicalTrial.gov Identifier: NCT03582761.
- Published
- 2019
20. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18 years or older: A randomized, double-blind, placebo-controlled, phase 1/2 trial
- Author
-
Lili Huang, Shihe Huang, Wenhui Wang, Wei Zhang, Shengli Xia, Xiaoxiao Gao, Wei Chen, Wangyang You, Wanshen Guo, Xing-Hang Li, Zhiming Yuan, Du Jianhui, Xin Wan, Wei Zhou, Shuo Shen, Xiaoming Yang, Zhiqiang Xie, Huajun Zhang, Zhengli Shi, Dongyang Zhao, Cheng Peng, Yongli Yang, Cong Wu, Lianghao Zhang, Zejun Wang, Xue-Wei Wang, Y. Wang, Yan-Bo Zhang, Yuntao Zhang, Xinguo Li, Yunkai Yang, Qian Wang, Jia Lu, Xuanxuan Nian, Xuqin Yang, Jing Guo, Kai Duan, and An Pan
- Subjects
medicine.medical_specialty ,Medicine (General) ,Research paper ,biology ,business.industry ,medicine.medical_treatment ,Immunogenicity ,General Medicine ,Placebo ,Vaccination ,Clinical trial ,R5-920 ,Internal medicine ,Inactivated vaccine ,medicine ,biology.protein ,Adverse effect ,business ,Neutralizing antibody ,Adjuvant - Abstract
Background We aimed to assess the safety and immunogenicity of an inactivated vaccine against COVID-19 in Chinese adults aged ≥18 years. Methods This is an ongoing randomized, double-blind, placebo-controlled, phase 1/2 clinical trial among healthy adults aged ≥18 years in Henan Province, China. Participants (n = 336 in 18–59 age group and n = 336 in ≥60 age group) were enrolled between April 12 and May 17 2020, and were equally randomized to receive vaccine or placebo (aluminum hydroxide adjuvant) in a three-dose schedule of 2·5, 5, or 10 µg on days 0, 28, and 56. Another 448 adults aged 18–59 years were equally allocated to four groups (a one-dose schedule of 10 µg, and two-dose schedules of 5 µg on days 0 and 14/21/28) and received vaccine or placebo (ratio 3:1 within each group). The primary outcomes were 7-day post-injection adverse reactions and neutralizing antibody titres on days 28 and 90 after the whole-course vaccination. Trial registration: www.chictr.org.cn #ChiCTR2000031809. Findings The 7-day adverse reactions occurred in 4·8% to 32·1% of the participants in various groups, and most adverse reactions were mild, transient, and self-limiting. Twenty participants reported 68 serious adverse events which were judged to be unrelated to the vaccine. The 90-day post-injection geometric mean titres of neutralizing antibody ranged between 87 (95% CI: 61–125) and 129 (99–169) for three-dose schedule among younger and older adults; 20 (14–27), 53 (38–75), and 44 (32–61) in 5 µg days 0 and 14/21/28 groups, respectively, and 7 (6–9) in one-dose 10 µg group. There were no detectable antibody responses in all placebo groups. Interpretation The inactivated vaccine against COVID-19 was well tolerated and immunogenic in both younger and older adults. The two-dose schedule of 5 µg on days 0 and 21/28 and three-dose schedules on days 0, 28, and 56 could be further evaluated for long-term safety and efficacy in the phase 3 trials. Funding The study was funded by the National Program on Key Research Project of China (2020YFC0842100) and Major Science and Technology Project of the National New Drug Development of China (2018ZX09734-004).
- Published
- 2021
21. Identification of an IRGP Signature to Predict Prognosis and Immunotherapeutic Efficiency in Bladder Cancer
- Author
-
Zhaowei Zhu, Longqing Li, Xuepei Zhang, Lianghao Zhang, and Yonghao Zhan
- Subjects
Tumor microenvironment ,Bladder cancer ,Stromal cell ,Microarray ,medicine.medical_treatment ,immune-related gene pair ,Computational biology ,Immunotherapy ,TCGA ,Biology ,medicine.disease ,Biochemistry, Genetics and Molecular Biology (miscellaneous) ,Biochemistry ,bioinformatic analysis ,lcsh:Biology (General) ,Lasso (statistics) ,immunotherapy response ,Consensus clustering ,Cox proportional hazards regression ,medicine ,bladder cancer ,Molecular Biosciences ,lcsh:QH301-705.5 ,Molecular Biology ,Original Research - Abstract
BackgroundIdentify immune-related gene pairs (IRGPs) signature related to the prognosis and immunotherapeutic efficiency for bladder cancer (BLCA) patients.Materials and MethodsOne RNA-seq dataset (The Cancer Genome Atlas Program) and two microarray datasets (GSE13507 and GSE31684) were included in this study. We defined these cohorts as training set to construct IRGPs and one immunotherapy microarray dataset as validation set. Identifying BLCA subclasses based on IRGPs by consensus clustering. The Lasso penalized Cox proportional hazards regression model was used to construct prognostic signature and potential molecular mechanisms were analyzed.ResultsThis signature can accurately predict the overall survival of BLCA patients and was verified in the immunotherapy validation set. IRGP-signatures can be used as independent prognostic risk factor in various clinical subgroups. Use the CIBERSORT algorithm to assess the abundance of infiltrating immune cells in each sample, and combine the results of the gene set enrichment analysis of a single sample to explore the differences in the immune microenvironment between IRPG signature groups. According to the results of GSVA, GSEA, and CIBERSORT algorithm, we found that IRGP is strikingly positive correlated with tumor microenvironment (TME) stromal cells infiltration, indicating that the poor prognosis and immunotherapy might be caused partly by enrichment of stromal cells. Finally, the results from the TIDE analysis revealed that IRGP could efficiently predict the response of immunotherapy in BLCA.ConclusionThe novel IRGP signature has a significant prognostic value for BLCA patients might facilitate personalized for immunotherapy.
- Published
- 2021
- Full Text
- View/download PDF
22. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials
- Author
-
Ziyan Meng, Y. Wang, Dongyang Zhao, Zhiqiang Xie, Jia Lu, Xiaoxiao Gao, Zhiming Yuan, Wei Zhou, Wenhui Wang, Jing Guo, Du Jianhui, An Pan, Xuqin Yang, Xin Wan, Xiaoming Yang, Lili Huang, Zhengli Shi, Cheng Peng, Wei Chen, Yan-Bo Zhang, Zejun Wang, Shihe Huang, Huajun Zhang, Yongli Yang, Cong Wu, Shengli Xia, Yunkai Yang, Wanshen Guo, Qian Wang, Wei Zhang, Xue-Wei Wang, Kai Duan, Xinguo Li, Shuo Shen, Wangyang You, Yuntao Zhang, and Lianghao Zhang
- Subjects
Adult ,Male ,medicine.medical_specialty ,COVID-19 Vaccines ,Adolescent ,Pneumonia, Viral ,Dose-Response Relationship, Immunologic ,Aluminum Hydroxide ,Antibodies, Viral ,01 natural sciences ,Injections, Intramuscular ,law.invention ,03 medical and health sciences ,Young Adult ,Betacoronavirus ,0302 clinical medicine ,Immunogenicity, Vaccine ,Randomized controlled trial ,Adjuvants, Immunologic ,Double-Blind Method ,law ,Internal medicine ,Propiolactone ,medicine ,Humans ,030212 general & internal medicine ,0101 mathematics ,Adverse effect ,Pandemics ,Randomized Controlled Trials as Topic ,business.industry ,SARS-CoV-2 ,Immunogenicity ,Viral Vaccine ,010102 general mathematics ,COVID-19 ,Viral Vaccines ,General Medicine ,Preliminary Communication ,Interim analysis ,Antibodies, Neutralizing ,Clinical trial ,Vaccination ,Vaccines, Inactivated ,Inactivated vaccine ,Female ,business ,Coronavirus Infections - Abstract
Importance A vaccine against coronavirus disease 2019 (COVID-19) is urgently needed. Objective To evaluate the safety and immunogenicity of an investigational inactivated whole-virus COVID-19 vaccine in China. Interventions In the phase 1 trial, 96 participants were assigned to 1 of the 3 dose groups (2.5, 5, and 10 μg/dose) and an aluminum hydroxide (alum) adjuvant-only group (n = 24 in each group), and received 3 intramuscular injections at days 0, 28, and 56. In the phase 2 trial, 224 adults were randomized to 5 μg/dose in 2 schedule groups (injections on days 0 and 14 [n = 84] vs alum only [n = 28], and days 0 and 21 [n = 84] vs alum only [n = 28]). Design, setting, and participants Interim analysis of ongoing randomized, double-blind, placebo-controlled, phase 1 and 2 clinical trials to assess an inactivated COVID-19 vaccine. The trials were conducted in Henan Province, China, among 96 (phase 1) and 224 (phase 2) healthy adults aged between 18 and 59 years. Study enrollment began on April 12, 2020. The interim analysis was conducted on June 16, 2020, and updated on July 27, 2020. Main outcomes and measures The primary safety outcome was the combined adverse reactions 7 days after each injection, and the primary immunogenicity outcome was neutralizing antibody response 14 days after the whole-course vaccination, which was measured by a 50% plaque reduction neutralization test against live severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Results Among 320 patients who were randomized (mean age, 42.8 years; 200 women [62.5%]), all completed the trial up to 28 days after the whole-course vaccination. The 7-day adverse reactions occurred in 3 (12.5%), 5 (20.8%), 4 (16.7%), and 6 (25.0%) patients in the alum only, low-dose, medium-dose, and high-dose groups, respectively, in the phase 1 trial; and in 5 (6.0%) and 4 (14.3%) patients who received injections on days 0 and 14 for vaccine and alum only, and 16 (19.0%) and 5 (17.9%) patients who received injections on days 0 and 21 for vaccine and alum only, respectively, in the phase 2 trial. The most common adverse reaction was injection site pain, followed by fever, which were mild and self-limiting; no serious adverse reactions were noted. The geometric mean titers of neutralizing antibodies in the low-, medium-, and high-dose groups at day 14 after 3 injections were 316 (95% CI, 218-457), 206 (95% CI, 123-343), and 297 (95% CI, 208-424), respectively, in the phase 1 trial, and were 121 (95% CI, 95-154) and 247 (95% CI, 176-345) at day 14 after 2 injections in participants receiving vaccine on days 0 and 14 and on days 0 and 21, respectively, in the phase 2 trial. There were no detectable antibody responses in all alum-only groups. Conclusions and relevance In this interim report of the phase 1 and phase 2 trials of an inactivated COVID-19 vaccine, patients had a low rate of adverse reactions and demonstrated immunogenicity; the study is ongoing. Efficacy and longer-term adverse event assessment will require phase 3 trials. Trial registration Chinese Clinical Trial Registry Identifier: ChiCTR2000031809.
- Published
- 2020
23. The feasibility of convalescent plasma therapy in severe COVID- 19 patients: a pilot study
- Author
-
Yue Wang, Yeqin Hu, Jianhong Yu, Wei Zhang, Shihe Huang, Kai Duan, Jifeng Hou, Hu Yong, Min Zhou, Huajun Zhang, Zejun Wang, Jiayou Zhang, Shengli Meng, Kun Deng, Huichuan Yang, Lianghao Zhang, Yanping Yu, Sai-Juan Chen, Zhou Zhijun, Ding Yu, Li Li, Xiaoxiao Gao, Xinxin Zhang, Bende Liu, Xiaoming Yang, Peng Yan, Zhengli Shi, Li Cesheng, Li Chen, Mingchao Yuan, Xiaobei Zheng, Ying Liu, Jinyan Huang, Dongbo Zhou, Cheng Peng, Wei Chen, Xuefei Liu, Xiao Wu, Jieming Qu, Bei Li, Xiaoqi Yu, Lin Lianzhen, Zhang Zhi, Zhiwu Xia, Ting Yu, Dan Wang, Gong Qin, and Zhu Chen
- Subjects
medicine.medical_specialty ,biology ,business.industry ,Lymphocyte ,Viremia ,medicine.disease ,Gastroenterology ,law.invention ,medicine.anatomical_structure ,Randomized controlled trial ,law ,Internal medicine ,medicine ,biology.protein ,Clinical endpoint ,Antibody ,business ,Neutralizing antibody ,Adverse effect ,Viral load - Abstract
Currently, there are no approved specific antiviral agents for 2019 novel coronavirus disease (COVID-19). In this study, ten severe patients confirmed by real-time viral RNA test were enrolled prospectively. One dose of 200 mL convalescent plasma (CP) derived from recently recovered donors with the neutralizing antibody titers above 1:640 was transfused to the patients as an addition to maximal supportive care and antiviral agents. The primary endpoint was the safety of CP transfusion. The second endpoints were the improvement of clinical symptoms and laboratory parameters within 3 days after CP transfusion. The median time from onset of illness to CP transfusion was 16.5 days. After CP transfusion, the level of neutralizing antibody increased rapidly up to 1:640 in five cases, while that of the other four cases maintained at a high level (1:640). The clinical symptoms were significantly improved along with increase of oxyhemoglobin saturation within 3 days. Several parameters tended to improve as compared to pre-transfusion, including increased lymphocyte counts (0.65×109/L vs. 0.76×109/L) and decreased C-reactive protein (55.98 mg/L vs. 18.13 mg/L). Radiological examinations showed varying degrees of absorption of lung lesionswithin 7 days. The viral load was undetectable after transfusion in seven patients who had previous viremia. No severe adverse effects were observed. This study showed CP therapy was welltolerated and could potentially improve the clinical outcomes through neutralizing viremia in severe COVID-19 cases. The optimal dose and time point, as well as the clinical benefit of CP therapy, needs further investigation in larger well-controlled trials.Significance StatementCOVID-19 is currently a big threat to global health. However, no specific antiviral agents are available for its treatment. In this work, we explored the feasibility of convalescent plasma (CP) transfusion to rescue severe patients. The results from 10 severe adult cases showed that one dose (200 mL) of CP was welltolerated and could significantly increase or maintain the neutralizing antibodies at a high level, leading to disappearance of viremia in 7 days. Meanwhile, clinical symptoms and paraclinical criteria rapidly improved within 3 days. Radiological examination showed varying degrees of absorption of lung lesions within 7 days. These results indicate that CP can serve as a promising rescue option for severe COVID-19 while the randomized trial is warranted.
- Published
- 2020
24. Long Non-Coding RNA CASC9 Promotes Bladder Cancer Tumorigenicity and Metastasis via Modulating FZD6/Wnt/β-catenin Signaling Pathway
- Author
-
Xuepei Zhang, Liqun Zhou, Shuanbao Yu, Lianghao Zhang, Yuchen Liu, Yonghao Zhan, and Xuesong Li
- Subjects
Gene knockdown ,Bladder cancer ,business.industry ,Mechanism (biology) ,Cancer research ,Wnt signaling pathway ,medicine ,Institutional Animal Care and Use Committee ,Signal transduction ,medicine.disease ,business ,Long non-coding RNA ,Metastasis - Abstract
Background: Accumulating evidence have highlighted the importance of long noncoding RNAs (lncRNAs) in multiple cancers development and progression. Cancer susceptibility candidate 9 (CASC9) is a novel long non-coding RNA and plays important regulatory role in diverse biological processes of cancers. However, the clinical significance and molecular mechanism of CASC9 in bladder cancer is still unknown. Methods: Comprehensive lncRNAs profiling analysis were conducted to identify lncRNAs profile alterations and uncover valuable lncRNA candidates for bladder cancer. The expression level of CASC9 was determined in a total of 106 patients with bladder cancer. Loss-of-function experiments were performed to identify the functions of CASC9 in tumor growth and metastasis of bladder cancer in vitro and in vivo. Bioinformatics analysis and further experiments were performed to explore the molecular mechanisms underlying the functions of CASC9. Findings: This study found that CASC9 expression was markedly upregulated in bladder cancer and related to histological grade, TNM stage and prognosis. Knockdown of CASC9 inhibited tumor growth and metastasis of bladder cancer in vitro and in vivo. Mechanistically, we found that CASC9 functions as a miRNA sponge to positively regulate FZD6 expression and subsequently activates Wnt/β-catenin signaling pathway, thus playing an oncogenic role in bladder cancer pathogenesis. Interpretation: In summary, lncRNA CASC9 plays a critical regulatory role in bladder cancer. The CASC9/miR-497-5p/ FZD6 axis provides insights for regulatory mechanism of bladder cancer, and new strategies for clinical practice. Funding Statement: This work was supported by National Natural Science Foundation of China [81773257, 81972867, 81672546], China Postdoctoral Science Foundation [2019M662544], Natural Science Foundation of Guangdong (2018B030306023) and the Shenzhen Municipal Government of China (JCYJ20180507184642475). Declaration of Interests: The authors declare that they have no conflicts of interest. Ethics Approval Statement: All animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of The First Affiliated Hospital of Zhengzhou University and Peking University First Hospital (Beijing, China) and conducted in accordance with its recommendations and ethical regulations.
- Published
- 2020
25. Additional file 3 of Long non-coding RNA SOX2OT promotes the stemness phenotype of bladder cancer cells by modulating SOX2
- Author
-
Yonghao Zhan, Zhicong Chen, Shiming He, Yanqing Gong, Anbang He, Yifan Li, Lianghao Zhang, Xuepei Zhang, Fang, Dong, Xuesong Li, and Liqun Zhou
- Subjects
urologic and male genital diseases ,female genital diseases and pregnancy complications - Abstract
Additional file 3: Table S1. Summary of clinicopathological features of tissues of bladder cancer.
- Published
- 2020
- Full Text
- View/download PDF
26. Additional file 4 of Long non-coding RNA SOX2OT promotes the stemness phenotype of bladder cancer cells by modulating SOX2
- Author
-
Yonghao Zhan, Zhicong Chen, Shiming He, Yanqing Gong, Anbang He, Yifan Li, Lianghao Zhang, Xuepei Zhang, Fang, Dong, Xuesong Li, and Liqun Zhou
- Abstract
Additional file 4: Table S2. The primer sequences included in this study.
- Published
- 2020
- Full Text
- View/download PDF
27. Additional file 4 of Long non-coding RNA CASC9 promotes tumor growth and metastasis via modulating FZD6/Wnt/β-catenin signaling pathway in bladder cancer
- Author
-
Zhan, Yonghao, Lianghao Zhang, Shuanbao Yu, Jianguo Wen, Yuchen Liu, and Xuepei Zhang
- Abstract
Additional file 4: Supplementary Table 1. Summary of clinicopathological features of tissues of bladder cancer.
- Published
- 2020
- Full Text
- View/download PDF
28. Additional file 5 of Long non-coding RNA SOX2OT promotes the stemness phenotype of bladder cancer cells by modulating SOX2
- Author
-
Yonghao Zhan, Zhicong Chen, Shiming He, Yanqing Gong, Anbang He, Yifan Li, Lianghao Zhang, Xuepei Zhang, Fang, Dong, Xuesong Li, and Liqun Zhou
- Abstract
Additional file 5: Table S3. Results of Bioinformation analysis.
- Published
- 2020
- Full Text
- View/download PDF
29. Additional file 6 of Long non-coding RNA CASC9 promotes tumor growth and metastasis via modulating FZD6/Wnt/β-catenin signaling pathway in bladder cancer
- Author
-
Zhan, Yonghao, Lianghao Zhang, Shuanbao Yu, Jianguo Wen, Yuchen Liu, and Xuepei Zhang
- Abstract
Additional file 6. Supplemental Materials and Methods.
- Published
- 2020
- Full Text
- View/download PDF
30. Additional file 5 of Long non-coding RNA CASC9 promotes tumor growth and metastasis via modulating FZD6/Wnt/β-catenin signaling pathway in bladder cancer
- Author
-
Zhan, Yonghao, Lianghao Zhang, Shuanbao Yu, Jianguo Wen, Yuchen Liu, and Xuepei Zhang
- Abstract
Additional file 5: Supplementary Table 2. The primer sequences included in this study.
- Published
- 2020
- Full Text
- View/download PDF
31. Long non-coding RNA SOX2OT promotes the stemness phenotype of bladder cancer cells by modulating SOX2
- Author
-
Anbang He, Liqun Zhou, Shiming He, Yonghao Zhan, Lianghao Zhang, Dong Fang, Yanqing Gong, Zhicong Chen, Yifan Li, Xuepei Zhang, and Xuesong Li
- Subjects
0301 basic medicine ,Male ,Cancer Research ,SOX2 ,Mice, Nude ,Apoptosis ,Stem cell marker ,lcsh:RC254-282 ,miR-200c ,03 medical and health sciences ,Mice ,0302 clinical medicine ,Cancer stem cell ,medicine ,Biomarkers, Tumor ,Tumor Cells, Cultured ,Animals ,Humans ,Cell Proliferation ,SOX2OT ,Mice, Inbred BALB C ,Bladder cancer ,biology ,SOXB1 Transcription Factors ,Research ,CD44 ,Cancer ,Middle Aged ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,Prognosis ,Xenograft Model Antitumor Assays ,Long non-coding RNA ,Gene Expression Regulation, Neoplastic ,MicroRNAs ,030104 developmental biology ,Oncology ,Urinary Bladder Neoplasms ,030220 oncology & carcinogenesis ,biology.protein ,Cancer research ,Neoplastic Stem Cells ,Molecular Medicine ,Female ,RNA, Long Noncoding ,Stem cell - Abstract
Background Accumulating evidence indicates that long non-coding RNAs (lncRNAs) are potential biomarkers and key regulators of tumour development and progression. SOX2 overlapping transcript (SOX2OT) is a novel lncRNA that acts as a potential biomarker and is involved in the development of cancer and cancer stem cells. However, the clinical significance and molecular mechanism of SOX2OT in bladder cancer are still unknown. Methods The expression level of SOX2OT was determined by RT-qPCR in a total of 106 patients with urothelial bladder cancer and in different bladder cancer cell (BCC) lines. Bladder cancer stem cells (BCSCs) were isolated from BCCs using flow cytometry based on the stem cell markers CD44 and ALDH1. Loss-of-function experiments were performed to investigate the biological roles of SOX2OT in the stemness phenotype of BCSCs. Comprehensive transcriptional analysis, RNA FISH, dual-luciferase reporter assays and western blots were performed to explore the molecular mechanisms underlying the functions of SOX2OT. Results SOX2OT was highly expressed in bladder cancer, and increased SOX2OT expression was positively correlated with a high histological grade, advanced TNM stage and poor prognosis. Further experiments demonstrated that knockdown of SOX2OT inhibited the stemness phenotype of BCSCs. Moreover, inhibition of SOX2OT delayed xenograft tumour growth and decreased metastases in vivo. Mechanistically, we found that SOX2OT was mainly distributed in the cytoplasm and positively regulated SOX2 expression by sponging miR-200c. Furthermore, SOX2 overexpression reversed the SOX2OT silencing-induced inhibition of the BCSC stemness phenotype. Conclusion This study is the first to demonstrate that SOX2OT plays an important regulatory role in BCSCs and that SOX2OT may serve as a potential diagnostic biomarker and therapeutic target in bladder cancer.
- Published
- 2019
32. Meta-analysis of multiple hematological biomarkers as prognostic predictors of survival in bladder cancer
- Author
-
Longqing Li, Yafeng Fan, Junxiao Liu, Biao Dong, Jiange Wang, Zhaowei Zhu, Xuepei Zhang, and Lianghao Zhang
- Subjects
Oncology ,medicine.medical_specialty ,meta ,Systemic inflammation ,Metastasis ,03 medical and health sciences ,0302 clinical medicine ,Internal medicine ,medicine ,Humans ,Lymphocyte Count ,030212 general & internal medicine ,Stage (cooking) ,hematological markers ,Inflammation biomarkers ,Bladder cancer ,Platelet Count ,business.industry ,Carcinoma ,Hazard ratio ,General Medicine ,medicine.disease ,Confidence interval ,Urinary Bladder Neoplasms ,030220 oncology & carcinogenesis ,Meta-analysis ,ComputingMethodologies_DOCUMENTANDTEXTPROCESSING ,bladder cancer ,medicine.symptom ,business ,Systematic Review and Meta-Analysis ,Biomarkers ,Research Article - Abstract
Supplemental Digital Content is available in the text, Background: Accumulating emerging studies have demonstrated that systemic inflammation can obviously affect tumor occurrence and progression. Nevertheless, the prognostic value of hematological inflammation biomarkers in bladder cancer is controversial. Thus, we conducted a meta-analysis to evaluate the key hematological biomarkers with various clinical outcomes in bladder cancer. Methods: We used online databases PUBMED and EMBASE to search relevant studies published prior to August 2019. After collecting the basic characteristics and prognostic data from the studies included, overall survival (OS), cancer-specific survival (CSS) and progression-free survival (PFS) were used as primary results. Subgroup analyses were performed according to ethnicity, the number of samples, survival outcomes, the value of cut-off, follow-up time and metastasis stage. Results: Thirty-three independent studies with 17,087 bladder cancer patients were added in the present analysis. The collected results showed that the increased neutrophil-to-lymphocyte ratio was associated with a poor OS (hazard ratio [HR] = 1.48, 95% confidence interval [CI]: 1.32–1.67, P
- Published
- 2020
33. Meta-analysis of multiple hematological biomarkers as prognostic predictors of survival in bladder cancer.
- Author
-
Lianghao Zhang, Longqing Li, Junxiao Liu, Jiange Wang, Yafeng Fan, Biao Dong, Zhaowei Zhu, Xuepei Zhang, Zhang, Lianghao, Li, Longqing, Liu, Junxiao, Wang, Jiange, Fan, Yafeng, Dong, Biao, Zhu, Zhaowei, and Zhang, Xuepei
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.